Dr. Christopher R. D'angelo, M.D.
Hematology (Hematology (Internal Medicine) Physician)
- Medicare participating
At a glance
- Medical school
- University of Illinois College of Med (Chi/Peor/Rock/Chm-Urb) (2013)
- Years since graduation
- 13
- In the NPI registry since
- 2013
- Medicare patients seen, 2024
- 234
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2013Medical school: University of Illinois College of Med (Chi/Peor/Rock/Chm-Urb)
- 2013Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology (Internal Medicine) Physician primary
NE license 32587 -
Hematology & Oncology Physician
NE license 32587 · WI license 65153-20
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- The Nebraska Medical Center Omaha, NE
- Bellevue Medical Center Bellevue, NE
Medical groups
- Unmc Physicians (1,518 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 234
- Services billed
- 809
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 316 | 79 |
| Established patient office or other outpatient visit, 40-54 minutes | 169 | 71 |
| Established patient office or other outpatient visit, 20-29 minutes | 124 | 86 |
| Established patient office or other outpatient visit, 30-39 minutes | 95 | 65 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 56 | 45 |
| Hospital discharge day management, 30 minutes or less | 30 | 28 |
| New patient office or other outpatient visit, 60-74 minutes | 20 | 20 |
| Hospital discharge day management, more than 30 minutes | 17 | 17 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Acyclovir Other prescribers in Omaha, NE | 94 |
| Revlimid (lenalidomide) | 47 |
| Sulfamethoxazole-Trimethoprim (sulfamethoxazole/trimethoprim) Other prescribers in Omaha, NE | 36 |
| Calquence (acalabrutinib maleate) | 30 |
| Allopurinol Other prescribers in Omaha, NE | 18 |
| Ondansetron Hcl Other prescribers in Omaha, NE | 14 |
| Prednisone Other prescribers in Omaha, NE | 13 |
| Imbruvica (ibrutinib) | 12 |
| Infanrix Dtap (diph,pertuss(acell),tet ped/pf) | 11 |
| Methotrexate (methotrexate sodium) Other prescribers in Omaha, NE | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 5 companies reported 21 payments worth $19,051 in total to this clinician.
| Adc Therapeutics America, Inc. | $14,787 |
|---|---|
| AbbVie Inc. | $3,654 |
| Abbott Laboratories | $478 |
| Beone Medicines USA, Inc. | $111 |
| Celgene Corporation | $21.02 |
| Honoraria | $13,500 |
|---|---|
| Consulting Fee | $3,575 |
| Travel and Lodging | $1,275 |
| Food and Beverage | $702 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Adc Therapeutics America, Inc. Sep 19, 2025 | Honoraria ZYNLONTA · ONCOLOGY | $13,500 |
| AbbVie Inc. Jan 17, 2025 | Consulting Fee VENCLEXTA · ONCOLOGY | $3,000 |
| Abbott Laboratories Feb 20, 2025 | Travel and Lodging AVEIR · Structural Heart · travel to New York, NY · in-kind | $469 |
| Adc Therapeutics America, Inc. Sep 12, 2025 | Travel and Lodging ZYNLONTA · ONCOLOGY · travel to DENVER, CO · in-kind | $465 |
| AbbVie Inc. Oct 14, 2025 | Consulting Fee VENCLEXTA · ONCOLOGY | $300 |
| Adc Therapeutics America, Inc. Sep 12, 2025 | Travel and Lodging ZYNLONTA · ONCOLOGY · travel to DENVER, CO · in-kind | $284 |
| AbbVie Inc. Jul 17, 2025 | Consulting Fee VENCLEXTA · ONCOLOGY | $275 |
| Adc Therapeutics America, Inc. Sep 13, 2025 | Travel and Lodging ZYNLONTA · ONCOLOGY · travel to DENVER, CO | $48.00 |
| Abbott Laboratories Feb 20, 2025 | Travel and Lodging AVEIR · Structural Heart · travel to New York, NY · in-kind | $9.02 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 9 industry-funded studies in 2025, from 6 companies. The companies reported $1,251,547 in research payments for these studies, mostly to the institutions running them.
- A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia
Beone Medicines USA, Inc. · Active, not recruiting · NCT06637501 - Study of Bcl-2 Inhibitor Sonrotoclax (BGB-11417) in Participants With Mature B-Cell Malignancies
Beone Medicines Ltd. · Active, not recruiting · NCT04277637 - Ph3 study of Pola R CHP Glofit vs PolaR CHP in 1L DLBCL
Genentech, Inc. - A Phase 1, Multicenter, Open-label Study to Evaluate the Safety and Preliminary Efficacy of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants with Relapsed and/or Refractory Multiple Myeloma …
Celgene Corporation - A Phase 1, Multicenter, Open-label Study to Evaluate the Safety and Preliminary Efficacy of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants with Relapsed and/or Refractory Multiple Myeloma …
E.r. Squibb & Sons, L.l.c. - Targeted BET BRD4 inhibition to enhance native t cell mediated lymphoma therapy abbvgmab3013, abbv744
AbbVie Inc. - Explore the activity of combinatory BET inhibition and Epcoritamab therapy in a BNHLT cell co culture model
AbbVie Inc. - An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma
Celgene Corporation · Completed · NCT03601078 - Expanded Access Protocol (EAP) for Patients Receiving Idecabtagene Vicleucel (ide-cel) that is Non-conforming for Commercial Release
E.r. Squibb & Sons, L.l.c.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.